Pidotimod(CAS 121808-62-6) is a synthetic dipeptide immunomodulatory API mainly applied in pediatric recurrent respiratory infections, chronic bronchitis and low-immunity auxiliary treatment. The 2026 price fluctuation of pharmaceutical-grade Pidotimod raw material is jointly driven by upstream intermediate cost, domestic API supply capacity, terminal preparation demand, medical policy supervision and overseas export orders. This paper sorts out the benchmark price baseline at the start of 2026, analyzes core price influencing factors, subdivides quarterly price fluctuation rhythm in 2026, distinguishes the price gap between qualified GMP bulk API and small-batch research-grade reagent, and summarizes medium-term price pressure and support logic for full-year trend judgment.
1. Baseline Price of Pidotimod at the Beginning of 2026
(1) Domestic pharmaceutical-grade bulk API (GMP qualified, 99% HPLC, 25kg industrial drum)
The weighted average factory transaction price in Q4 2025 was 1,246 RMB/kg, with mainstream market range of 1,180-1,320 RMB/kg. Entering Q1 2026, driven by the price hike of core intermediates L-pyroglutamic acid and thiazolidine-4-carboxylic acid, the average price rose slightly to 1,273 RMB/kg, with a quarter-on-quarter increase of 2.17% as the opening benchmark for 2026 full-year operation.
Integrated API-preparation manufacturers (Xianju Pharmaceutical, Jincheng Pharmaceutical) have internal self-supply cost 23.6% lower than outsourced raw materials, with internal transfer price stable at 1,080-1,150 RMB/kg, forming a price floor for the whole industry.
(2) Small-batch research-grade reagent & export-grade API
Lab-scale high-purity reagent (99.7%+, gram-level packaging) maintains a high premium, with overseas listed prices at USD 220-240/kg for bulk export samples, and small gram-level lab reagents at USD 30-150/g, independent of bulk API price fluctuation cycle. Small uncertified chemical workshop bulk goods are priced at 800–900 RMB/kg, but limited by drug filing and hospital procurement access, with low market share and no impact on mainstream pharmaceutical-grade price trend.
2. Core Factors Driving Pidotimod Price Fluctuation in 2026
(1) Upstream intermediate cost fluctuation (Primary cost driver)
Pidotimod synthesis relies on two key chiral intermediates: L-pyroglutamic acid and L-thiazolidine carboxylic acid, which account for more than 65% of total production cost of finished API.
In Q1-Q2 2026, tight supply of chiral amino acid intermediates pushes intermediate prices up 3%-5%, forming sustained upward cost pressure on Pidotimod bulk goods. In Q3, new intermediate production lines in Hubei and Anhui are put into operation to ease supply tension, intermediate prices pull back moderately, and API cost pressure weakens synchronously. Auxiliary raw materials such as condensation reagents and anhydrous solvents fluctuate slightly without obvious pull on overall cost.
(2) Domestic API supply capacity expansion (Major downward pressure factor)
By 2026, 7 mainstream GMP manufacturers occupy 73.6% of national output, with Hubei chemical clusters contributing 58.1% of total annual production capacity. 17 new preparation production lines are filed and launched in Shandong, Hebei and Anhui in 2026, driving upstream API annual total capacity up 28.7% year-on-year, overall industry capacity utilization remains at 72%-78% throughout the year, and oversupply restrains large-scale price surges. Small backward production lines without consistency evaluation qualifications continue to withdraw from the market, reducing low-cost disorderly dumping and supporting the bottom line of qualified API prices.
(3) Terminal medical demand changes (Demand-side support factor)
Domestic hospital demand: The 2025 national medical insurance catalog expands the reimbursement scope of Pidotimod oral preparations to children aged 6-12 with chronic bronchitis, and fixed-point hospital procurement volume increased 14.6% year-on-year in 2025, maintaining steady rigid demand in 2026; spring and autumn respiratory infection peak seasons (Q2, Q4) drive seasonal stocking of preparation factories and lift API short-term purchasing prices.
Overseas export incremental demand: Jincheng Pharmaceutical and other manufacturers complete ASEAN pre-certification in Q2 2026, launching bulk API exports to Vietnam, the Philippines and Indonesia; overseas orders add incremental demand of about 8-12 tons per year, partially absorbing excess domestic capacity and easing price decline pressure.
(4) Industry policy and centralized procurement regulation (Structural price dividing factor)
National drug centralized procurement expands the coverage of pediatric oral immunomodulatory preparations in 2026. Preparation manufacturers selected in volume-based bidding implement cost control, pushing them to sign long-term fixed-price supply contracts with integrated API factories at lower negotiated prices; non-bidding high-end pediatric specialized formulations have higher tolerance for API purchase prices, forming a two-tier differentiated pricing system in the market. At the same time, NMPA tightens impurity control standards for peptide APIs in 2026, raising production and testing costs of qualified manufacturers, and eliminating low-cost substandard products, which avoids vicious price competition at the bottom end of the market.
(5) Seasonal inventory cycle of preparation factories (Short-term quarterly fluctuation factor)
Preparation manufacturers concentrate raw material stocking before spring (April-May) and autumn (September-October) respiratory disease peaks, forming two seasonal demand peaks each year, which trigger short-term upward price adjustment of Pidotimod bulk API; in off-season Q1 and Q3, downstream stocking slows, inventory pressure of API factories rises, and transaction prices are slightly discounted to stimulate shipments.
3. Quarterly Phased Price Trend Forecast of Pidotimod Bulk API in 2026
(1) Q1 2026 (January-March): Slight high opening, narrow range consolidation
Average factory price: 1,260-1,290 RMB/kg, central benchmark 1,273 RMB/kg.
Affected by the carry-over price increase of upstream intermediates at the end of 2025, the market opens slightly higher; downstream preparation factories maintain minimal safety inventory after the Spring Festival holiday, overall purchasing willingness is weak, API manufacturers have sufficient inventory, and the price lacks continuous upward momentum, fluctuating within a narrow range without obvious rise or fall.
(2) Q2 2026 (April-June): Seasonal upward fluctuation, peak price of the whole year
Average factory price: 1,290-1,340 RMB/kg, annual price peak appears in mid-May.
Spring recurrent respiratory infections drive preparation factory centralized stocking; ASEAN export orders are released in batches after Q2 certification, dual demand superposition pushes up transaction prices. New intermediate production lines start trial production at the end of June, cost pressure eases marginally, and prices begin to fall back at the end of Q2. The upper price limit is restricted by abundant overall industry capacity, with no sharp surge exceeding 1,350 RMB/kg.
(3) Q3 2026 (July-September): Off-season price correction, full-year price trough
Average factory price: 1,220-1,260 RMB/kg, the lowest central price of the whole year is around mid-August.
Summer is the off-season for respiratory infection drugs, downstream stocking volume shrinks significantly; intermediate raw material supply is fully released, production costs decline; API factories accelerate inventory clearance through small discounts, driving the market price to the annual low point. Integrated manufacturers rely on stable internal preparation demand to maintain transfer prices above 1,100 RMB/kg, forming a solid price bottom line to prevent sharp price collapse.
(4) Q4 2026 (October-December): Rebound supported by autumn demand, slight year-end correction
Average factory price: 1,250-1,300 RMB/kg.
Autumn cold and respiratory infection season brings the second stocking peak of the year, pushing prices to rebound from Q3 lows. At the end of December, preparation factories complete annual inventory verification and reduce raw material purchasing volume; API factories cut production appropriately to balance inventory, and prices fall slightly before the year-end holiday. The full-year closing average price is expected to stabilize at about 1,260 RMB/kg, basically flat with the Q1 opening price.
4. Price Differentiation Pattern in 2026 Market Segments
(1) GMP-certified bulk pharmaceutical API (Mainstream transaction market)
Long-term annual framework orders signed by large preparation groups: fixed negotiated price 1,190-1,250RMB/kg, stable with small fluctuation range, immune to short-term seasonal spot price spikes.
Spot bulk orders for medium and small preparation factories: follow quarterly seasonal rhythm, with a fluctuation range of ±40-70RMB/kg based on the annual average price, the main reference benchmark for market price changes.
(2) Export-grade bulk API for Southeast Asia
Export FOB price maintains USD 220-240/kg throughout 2026, slightly higher than domestic spot RMB equivalent price, supported by overseas certification premium and stable foreign currency settlement; export volume accounts for less than 10% of total domestic output, unable to reverse the overall domestic supply and demand cycle trend.
(3) Lab research reagent grade Pidotimod
Gram-level high-purity analytical reagents are supplied by fine chemical manufacturers, with prices decoupled from bulk pharmaceutical raw materials, maintaining high premium throughout the year without obvious quarterly fluctuation, mainly serving university laboratories and pharmaceutical R&D institutions, with a small market scale.
5. Key Risks Affecting the Deviation of 2026 Price Trend
(1) Upward risk factors that push prices higher than forecast
Force majeure such as environmental protection inspections or safety shutdowns in major Hubei API production bases leads to short-term supply shortage;
Continuous tight supply of chiral intermediates, with intermediate prices rising more than expected and transmitting cost pressure to finished API;
Sudden surge in domestic pediatric respiratory infection incidence, preparation factories overstock raw materials in advance, triggering spot price rush buying.
(2) Downward risk factors that pull prices lower than forecast
Multiple new API production lines reach full production in advance, industry capacity surplus intensifies, and manufacturers launch large-scale discount promotions to seize share;
The scope of national centralized procurement is expanded, and the bid-winning price of preparations drops sharply, forcing API suppliers to cut long-term contract prices;
Rapid market penetration of alternative immunomodulatory drugs (thymosin, transfer factor) reduces terminal demand for Pidotimod preparations and weakens raw material purchasing support.
6. Full-Year Comprehensive Trend Conclusion of Pidotimod Price in 2026
Overall annual trend: Narrow-range shock consolidation, presenting a typical "double peak and double trough" seasonal fluctuation pattern, with the annual average factory price of pharmaceutical-grade bulk API centered at 1,260-1,280 RMB/kg, the overall fluctuation amplitude controlled within ±5% year-on-year, no sharp bull or bear market.
Core support logic: Steady rigid demand of domestic medical insurance terminal + incremental overseas export orders+elimination of substandard low-cost raw materials jointly support the bottom line of qualified API prices, avoiding continuous sharp decline.
Core ceiling restriction logic: Sustained expansion of domestic API total capacity restricts large-scale price surges; centralized procurement cost control of terminal preparations inhibits the long-term upward space of raw material prices.
Seasonal operation law: Q2 spring stocking is the best price peak window of the whole year; Q3 summer off-season is the low-price purchasing window for downstream preparation factories; Q4 autumn demand brings a moderate secondary rebound, with the year-end price returning close to the opening level of Q1.
